Anti-HER2 ribozyme - Elan/Sirna

Drug Profile

Anti-HER2 ribozyme - Elan/Sirna

Alternative Names: Anti-HER2 ribozyme - Elan/Sirna; Herzyme

Latest Information Update: 08 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elan Pharmaceutical Technologies; Sirna Therapeutics
  • Developer Sirna Therapeutics
  • Class Antineoplastics; Ribozymes
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co
  • 22 Jul 2003 Data presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR-2003) have been added to the adverse events and pharmacokinetics section
  • 17 Apr 2003 Ribozyme Pharmaceuticals is now called Sirna Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top